Literature DB >> 20458634

Assessment of free dye in solutions of dual-labeled antibody conjugates for in vivo molecular imaging.

Melissa B Aldrich1, Xuejuan Wang, Amy Hart, Sunkuk Kwon, Lakshmi Sampath, Milton V Marshall, Eva M Sevick-Muraca.   

Abstract

PURPOSE: Recent preclinical and clinical studies show that dyes that excite and fluoresce in the near-infrared range may be used for tracking and detecting disease targets in vivo. A method for quantifying free dye molecules in antibody conjugate preparations is required for agent batch release and for translation into the clinic. PROCEDURES: Herein, we developed and validated a SDS-PAGE method to determine the percentage of free IRDye 800 CW in (DTPA)(n)-trastuzumab-(IRDye 800)(m) conjugate sample preparations in which high-performance liquid chromatography (HPLC) assessment of free dye was not possible.
RESULTS: The SDS-PAGE assay was accurate and valid for free IRDye 800 CW amounts between 38 and 4 mol% of total dye. Gel sample preparation reagent affected the specificity of the assay, and lower and upper limits of quantitation and detection were determined.
CONCLUSION: This method may be applicable to other near-infrared dye-conjugated antibody-based imaging agents in which HPLC assessment of purity is not feasible. This validated method for quality assurance will facilitate the translation of dual-labeled antibody conjugates for nuclear and optical imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20458634      PMCID: PMC5312670          DOI: 10.1007/s11307-010-0328-7

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  31 in total

1.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.

Authors:  R Simon; A Nocito; T Hübscher; C Bucher; J Torhorst; P Schraml; L Bubendorf; M M Mihatsch; H Moch; K Wilber; A Schötzau; J Kononen; G Sauter
Journal:  J Natl Cancer Inst       Date:  2001-08-01       Impact factor: 13.506

2.  Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody.

Authors:  B L Engelstad; L E Spitler; M J Del Rio; E C Ramos; L L Rosendorf; C E Reinhold; A Khentigan; J P Huberty; S W Corpuz; H M Lee
Journal:  Radiology       Date:  1986-11       Impact factor: 11.105

3.  Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody.

Authors:  A M Keenan; J N Weinstein; J L Mulshine; J A Carrasquillo; P A Bunn; J C Reynolds; S M Larson
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

4.  Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma.

Authors:  W B Nelp; J F Eary; R F Jones; K E Hellstrom; I Hellstrom; P L Beaumier; K A Krohn
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

Review 5.  Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.

Authors:  Rita Nanda
Journal:  Rev Recent Clin Trials       Date:  2007-05

6.  Kinetics of interstitially administered monoclonal antibodies for purposes of lymphoscintigraphy.

Authors:  R L Wahl; O Geatti; M Liebert; B Wilson; P Shreve; B A Beers
Journal:  J Nucl Med       Date:  1987-11       Impact factor: 10.057

7.  Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Authors:  Lakshmi Sampath; Sunkuk Kwon; Shi Ke; Wei Wang; Rachel Schiff; Michel E Mawad; Eva M Sevick-Muraca
Journal:  J Nucl Med       Date:  2007-09       Impact factor: 10.057

Review 8.  HER2/neu in systemic therapy for women with breast cancer: a systematic review.

Authors:  Bindi Dhesy-Thind; Kathleen I Pritchard; Hans Messersmith; Frances O'Malley; Leela Elavathil; Maureen Trudeau
Journal:  Breast Cancer Res Treat       Date:  2007-07-17       Impact factor: 4.872

Review 9.  Near infrared fluorescent optical imaging for nodal staging.

Authors:  Lakshmi Sampath; Wei Wang; Eva M Sevick-Muraca
Journal:  J Biomed Opt       Date:  2008 Jul-Aug       Impact factor: 3.170

Review 10.  Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Authors:  Christina H Yeon; Mark D Pegram
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.651

View more
  5 in total

1.  Preclinical characterization and validation of a dual-labeled trastuzumab-based imaging agent for diagnosing breast cancer.

Authors:  Xuejuan Wang; Melissa B Aldrich; Milton V Marshall; Eva M Sevick-Muraca
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

Review 2.  Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis.

Authors:  Ali Azhdarinia; Pradip Ghosh; Sukhen Ghosh; Nathaniel Wilganowski; Eva M Sevick-Muraca
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

3.  Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging.

Authors:  Jacqueline Pei; Georgina Juniper; Nynke S van den Berg; Naoki Nisho; Trevor Broadt; Anthony R Welch; Grace S Yi; Roan C Raymundo; Stefania U Chirita; Guolan Lu; Giri Krishnan; Yu-Jin Lee; Shrey Kapoor; Quan Zhou; A Dimitrios Colevas; Natalie S Lui; George A Poultsides; Gordon Li; Kurt R Zinn; Eben L Rosenthal
Journal:  Mol Imaging Biol       Date:  2020-09-03       Impact factor: 3.484

4.  Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.

Authors:  Cornelius Cilliers; Ian Nessler; Nikolas Christodolu; Greg M Thurber
Journal:  Mol Pharm       Date:  2017-03-31       Impact factor: 4.939

5.  Seeing it through: translational validation of new medical imaging modalities.

Authors:  Melissa B Aldrich; Milton V Marshall; Eva M Sevick-Muraca; Greg Lanza; John Kotyk; Joseph Culver; Lihong V Wang; Jashim Uddin; Brenda C Crews; Lawrence J Marnett; Joseph C Liao; Chris Contag; James M Crawford; Ken Wang; Bill Reisdorph; Henry Appelman; D Kim Turgeon; Charles Meyer; Tom Wang
Journal:  Biomed Opt Express       Date:  2012-03-22       Impact factor: 3.732

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.